| Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2) E Wajs, L Aluisio, R Holder, EJ Daly, R Lane, P Lim, JE George, ... The Journal of clinical psychiatry 81 (3), 10773, 2020 | 254 | 2020 |
| Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat C Dugovic, JE Shelton, LE Aluisio, IC Fraser, X Jiang, SW Sutton, ... The Journal of pharmacology and experimental therapeutics 330 (1), 142-151, 2009 | 254 | 2009 |
| Selective blockade of 5-hydroxytryptamine (5-HT) 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by … P Bonaventure, L Kelly, L Aluisio, J Shelton, B Lord, R Galici, K Miller, ... The Journal of pharmacology and experimental therapeutics 321 (2), 690-698, 2007 | 213 | 2007 |
| Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567 A Bhattacharya, Q Wang, H Ao, JR Shoblock, B Lord, L Aluisio, I Fraser, ... British journal of pharmacology 170 (3), 624-640, 2013 | 204 | 2013 |
| Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonist AJ Barbier, C Berridge, C Dugovic, AD Laposky, SJ Wilson, J Boggs, ... British journal of pharmacology 143 (5), 649-661, 2004 | 199 | 2004 |
| Histamine H3 receptor antagonists: from target identification to drug leads P Bonaventure, M Letavic, C Dugovic, S Wilson, L Aluisio, C Pudiak, ... Biochemical pharmacology 73 (8), 1084-1096, 2007 | 173 | 2007 |
| Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement JR Shoblock, N Welty, L Aluisio, I Fraser, ST Motley, K Morton, J Palmer, ... Psychopharmacology 215, 191-203, 2011 | 169 | 2011 |
| Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder P Bonaventure, C Dugovic, M Kramer, P De Boer, J Singh, S Wilson, ... The Journal of Pharmacology and Experimental Therapeutics 342 (2), 429-440, 2012 | 100 | 2012 |
| Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia P Bonaventure, J Shelton, S Yun, D Nepomuceno, S Sutton, L Aluisio, ... The Journal of Pharmacology and Experimental Therapeutics 354 (3), 471-482, 2015 | 95 | 2015 |
| Novel substituted 4-phenyl-[1, 3] dioxanes: potent and selective orexin receptor 2 (OX2R) antagonists LC McAtee, SW Sutton, DA Rudolph, X Li, LE Aluisio, VK Phuong, ... Bioorganic & medicinal chemistry letters 14 (16), 4225-4229, 2004 | 91 | 2004 |
| A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical … CC Chrovian, A Soyode-Johnson, AA Peterson, CF Gelin, X Deng, ... Journal of Medicinal Chemistry 61 (1), 207-223, 2018 | 80 | 2018 |
| Pharmacology of a novel central nervous system–penetrant P2X7 antagonist JNJ-42253432 B Lord, L Aluisio, JR Shoblock, RA Neff, EI Varlinskaya, M Ceusters, ... The Journal of pharmacology and experimental therapeutics 351 (3), 628-641, 2014 | 79 | 2014 |
| Lead identification of acetylcholinesterase inhibitors–histamine H3 receptor antagonists from molecular modeling SD Bembenek, JM Keith, MA Letavic, R Apodaca, AJ Barbier, L Dvorak, ... Bioorganic & medicinal chemistry 16 (6), 2968-2973, 2008 | 79 | 2008 |
| Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia A Bhattacharya, B Lord, JS Grigoleit, Y He, I Fraser, SN Campbell, ... Neuropsychopharmacology 43 (13), 2586-2596, 2018 | 76 | 2018 |
| Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex W Si, L Aluisio, N Okamura, SD Clark, I Fraser, SW Sutton, P Bonaventure, ... Journal of neurochemistry 115 (2), 475-482, 2010 | 67 | 2010 |
| JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition R Galici, JD Boggs, L Aluisio, IC Fraser, P Bonaventure, B Lord, ... Neuropharmacology 56 (8), 1131-1137, 2009 | 61 | 2009 |
| 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a … MA Letavic, BM Savall, BD Allison, L Aluisio, JI Andres, M De Angelis, ... Journal of Medicinal Chemistry 60 (11), 4559-4572, 2017 | 59 | 2017 |
| Pharmacological Blockade of Serotonin 5-HT7 Receptor Reverses Working Memory Deficits in Rats by Normalizing Cortical Glutamate Neurotransmission P Bonaventure, L Aluisio, J Shoblock, JD Boggs, IC Fraser, B Lord, ... PLoS One 6 (6), e20210, 2011 | 57 | 2011 |
| JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats R Galici, AH Rezvani, L Aluisio, B Lord, ED Levin, I Fraser, J Boggs, ... Psychopharmacology 214, 829-841, 2011 | 57 | 2011 |
| In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective … JR Shoblock, N Welty, D Nepomuceno, B Lord, L Aluisio, I Fraser, ... Psychopharmacology 208, 265-277, 2010 | 55 | 2010 |
